Please login to the form below

Not currently logged in

Shire appoints Soren Tulstrup to lead its MPS franchise

He joins with experience from Santaris Pharma, Merck & Co, Sandoz and Abbott

Soren Tulstrup has joined Shire's Human Genetic Therapies business as franchise lead, MPS (mucopolysaccharides).

He will be responsible for developing global strategy for the MPS franchise, where Shire's current lead product is Elaprase (idursulfase) for Hunter syndrome.

Tulstrup will also play a key role in strategic decisions made about the company's rare disease portfolio, which includes 2010 Prix Galien winner Firazyr (icatibant) and Fabry disease drug Replagal (agalsidase alfa).

In his new role, Tulstrup will report to Sylvie Grégoire, president of Shire HGT, and be based in Shire's office in Nyon, Switzerland.

“Shire HGT is well positioned for continued sustained growth, with a strong portfolio of therapies for patients suffering from rare genetic diseases and a pipeline with significant potential,” said Sylvie Grégoire, president, Shire HGT.

“We believe Soren's extensive global experience will be invaluable in maximising the full potential of the MPS franchise as we provide therapies to patients with rare conditions that enable them to lead better lives,”.

Currently vice chairman of trade association EBE (European Biopharmaceutical Enterprises), Tulstrup was formerly president and CEO of Santaris Pharma, where he led business development efforts resulting in four major partnership agreements, including an ongoing collaboration with Shire.

Prior to this he spent over a decade at Merck & Co, both in Europe and the US, and has also held sales and marketing positions at Sandoz and Abbott Laboratories.

31st July 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018